Microneedle transdermal delivery of compound betamethasone in alopecia areata-A randomized controlled trial

Rui Qiao,Jiaping Zhu,Jing Fang,Hualing Shi,Ziye Zhang,Jin Nie,Yiping Ge,Tong Lin,Yiqun Jiang
DOI: https://doi.org/10.1016/j.jaad.2024.09.059
2024-10-10
Abstract:Background: Alopecia areata (AA) places a considerable burden on patients. While intralesional glucocorticoid injection is an important therapy, it can cause severe pain. Objective: To compare the efficacy and pain levels of microneedle transdermal delivery of compound betamethasone versus traditional intralesional injection in mild-to-moderate AA. Methods: We conducted a randomized controlled trial in AA patients with a Severity of Alopecia Tool (SALT) score <50. Both groups received monthly compound betamethasone injections: group A via intralesional injections and group B via transdermal microneedle delivery. The primary outcome was the reduction in SALT score after 3 months. Results: With 80 patients enrolled, baseline SALT scores were similar between group A (9.250 ± 5.300) and group B (10.65 ± 9.445). After 3 months, the mean SALT reduction was 7.000 ± 4.5017 in group A and 8.075 ± 8.014 in group B, with no statistical difference. Remission rates for SALT30/50/75/90 were 92.50/90.00/57.50/42.50% in group A and 95.00/87.50/72.50/40% in group B, with no significant difference. Group B had a significantly lower visual analog scale pain score than group A (4.000 ± 1.174 vs 5.281 ± 2.098, P = .0047). Limitations: The study focused on mild-to-moderate patchy AA, limiting insights into severe cases. Conclusion: Microneedle transdermal delivery of compound betamethasone in mild-to-moderate patchy AA demonstrates efficacy comparable to traditional intralesional injection with reduced pain.
What problem does this paper attempt to address?